![Phase II Study of the GI-4000 KRAS Vaccine After Curative Therapy in Patients With Stage I-III Lung Adenocarcinoma Harboring a KRAS G12C, G12D, or G12V Mutation]()
Phase II Study of the GI-4000 KRAS Vaccine After Curative Therapy in Patients With Stage I-III Lung Adenocarcinoma Harboring a KRAS G12C, G12D, or G12V MutationChaft, Jamie E.; Litvak, Anya; Arcila, Maria E.; Patel, Payal; D'Angelo, Sandra P.; Krug, Lee M.; Rusch, Valerie; Mattson, Alicia; Coeshott, Claire; Park, Bernard; Apelian, David M.; Kris, Mark G.; Azzoli, Christopher G. · Clinical Lung Cancer · 2014